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A CLINICO PATHOLOGICAL STUDY OF 
MALIGNANT MELANOMA
INTRODUCTION
A malignant melanoma (MM) is a melanocyte-derived cancer, which most often is 
found in the skin (cutaneous malignant melanoma, CMM) but can be found in all organs that 
harbour melanocytes, e.g. the ears, the eyes, the mucosal membranes (nose, oral cavity, 
anorectal mucosa and the genitourinary mucosa), the central nervous system (leptomeningeal 
melanoma) and in the gastrointestinal tract. It is the most malignant skin cancer type and 
causes the majority of skin cancer related deaths. CMM is among  the most common types of 
cancer in young adults.  
AIM OF STUDY
 TO KNOW THE INCIDENSE OF  MALIGNANT MELANOMA  IN  OUR 
HOSPITAL
 TO STUDY THE VARIOUS  MODES  OF PRESENTATION  OF MALIGNANT 
MELANOMA
 TO ASSESS THE PROGNOSTIC FACTORS IN ORDER OF IMPORTANCE OF 
SURVIVAL SUCH AS LYMPH NODE STATUS, ULCERATION AND 
THICKNESS.
 TO EVALUATE THE VARIOUS  TREATMENT MODALITIES AND THEIR 
COMPLICATIONS, PROGNOSIS OF MALIGNANT MELANOMA IN OUR 
HOSPITAL
MATERIALS  AND  METHODS
Cases admitted in all surgical units of department of general surgery, dermatology 
department, plastic surgery department and oncology department in Stanley government 
hospital between may 2011 to December 2013 were taken in a random fashion for this study. 
This group of 30 patients were aged between 30 to72 years with a mean age of 50 yrs. Of 
these 18 were male and 12 female.
RESULTS
These 30 patients were divided into two main group. Group A were curative 
resection was planned and Group B were palliative treatment was planned.
GROUP A
Included 24 patients for curative resection
- no distant visceral metastasis
- no local fixity to surrounding important structures
- no fixed regional lymphnode
GROUP B 
Included 6 patients for palliative treatment
- Palliative resection (2 patients)
- Palliative chemotherapy (2 patients)
- Palliative radiotherapy (3 patients)
CONCLUSION
 Mean age at presentation was 50 years
 46.6% of patients had stage 3 disease at presentation
 Most of the cases in this series are extremities melanoma
 Curative wide local excision was possible in 63.3% of cases
 Blackish patches, ulcer and growth were the commonest complaints
 Prognosis of the patients in my study better in patients without ulceration and lymph 
node involvement
KEYWORDS
Malignant melanoma, wide local excision, radical lymph node dissection, satellite 
nodule, in transit lesion, skin, oral cavity, anal canal.
7INTRODUCTION
A malignant melanoma (MM) is a melanocyte-derived cancer, 
which most often is found in the skin (cutaneous malignant melanoma, 
CMM) but can be found in all organs that harbour melanocytes, e.g. the 
ears, the eyes, the mucosal membranes (nose, oral cavity, anorectal 
mucosa and the genitourinary mucosa), the central nervous system 
(leptomeningeal melanoma) and in the gastrointestinal tract. It is the 
most malignant skin cancer type and causes the majority of skin cancer 
related deaths. CMM is among the most common types of cancer in 
young adults.  
Melanomas can arise de novo in the skin (about 70%) or have a 
common nevus or a clinically atypical nevus as a precursor lesion.  As 
long as the CMM grows in the epidermis the tumour is characterized as 
in situ, but when it grows down in the dermis it is invasive with a 
potential to metastasize. The histopathological examination of a 
melanoma always includes the measure of depth in millimetre, 
according to Breslow, and the measure of invasion to different skin 
layers (I to V), according to Clark .
8AIM OF STUDY
 TO KNOW THE INCIDENSE OF  MALIGNANT 
MELANOMA  IN  OUR HOSPITAL
 TO STUDY THE VARIOUS  MODES  OF PRESENTATION  
OF MALIGNANT MELANOMA
 TO ASSESS THE PROGNOSTIC FACTORS IN ORDER OF 
IMPORTANCE OF SURVIVAL SUCH AS LYMPH NODE 
STATUS, ULCERATION AND THICKNESS.
 TO EVALUATE THE VARIOUS  TREATMENT 
MODALITIES AND THEIR COMPLICATIONS, PROGNOSIS 
OF MALIGNANT MELANOMA IN OUR HOSPITAL
 TO REVIEW THE LITERATURE ON MALIGNANT 
MELANOMA
9REVIEW OF LITERATURE
ANATOMY
The human skin is the largest organ with a surface area of 1.4-2m 
and consists of the three layers epidermis, dermis and subcutaneous 
tissue.In the skin hair follicles, sweat and sebaceous glands are found 
and the three basal layers are complemented and joined by three 
networks that link the skin to the rest of the body: cutaneous nerves, 
cutaneous blood vessels and lymphatics. These three networks provide 
e.g. nutrition and oxygen supply, and are vital for fluid balance, 
immune responses and skin sensation. The skin constitutes an important 
barrier against outer dangers as mechanical trauma, infections, chemical 
irritants, microorganism, Ultraviolet radiation (UVR) and free radicals 
(which can cause toxicity to DNA and cell membranes), toxins and 
heat. 
The most superficial part of the skin is the epidermis, an 
avascular layer, mainly composed of keratinocytes (KC) as well as 
smaller populations of pigment producing melanocytes (MC) and 
mechano sensory Merkel cells. The immune system is also present in 
the epidermis, as the migratory Langerhans cells and intra epidermal 
T-cells. Beneath the epidermis is the dermo epidermal junction with the 
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basal layer, and underlying this is the dermis, which mainly consists of 
connective tissue with eccrine glands and hair follicles, dermal 
fibroblasts and a nerve, complex network of vessels.  The third layer of 
the skin is the subcutaneous fat , providing a hormone factory and 
thermal insulation and acting as a shock absorber.   
Melanocytes  
Melanocytes are the neural crest-derived dendritic cells, which 
are present in the epidermis, in the uveal tract, in the leptomeninges , in 
the hair follicles and in the inner ear. They can also be found in the 
mucosal membranes and in gastrointestinal tract and common for all 
anatomical sites is that increased numbers of melanocytes. In the 
epidermis they are not unevenly dispersed along the basal layer at the 
dermo epidermal junction, where approximately every 8th cell is a 
melanocyte. This pigment production determines human hair and skin 
colour and protects the receiving cells nuclei/DNA from damage by UV 
light. The way that melanin protects the DNA is by absorption and 
scattering of the UVR . One melanocyte takes care of and provides 
melanin to up to 36 KCs in the surrounding area, named the epidermal 
melanin unit . They produce the pigment melanin (for melanogenesis 
see below) within melanosomes, organelles that are transferred to 
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surrounding keratinocytes and hair follicle cells. The synthesis and 
transfer of melanin are regulated by several paracrine  and autocrine 
factors, in response to both endogenous and exogenous stimuli, where 
UVR is one important factor .  The melanocytes are also susceptible to 
UVR and oxidative stress, factors that may cause genetic mutations in 
the melanocytes and thus capable of inducing malignant 
transformations. 
Melanin synthesis 
Melanin is produced in three versions , DHI-melanin [black] and  
the reddish-yellow pheomelanin and the brown-black eumelanins 
(DHICA-melanin [brown]. They have different functions where 
eumelanin is photoprotective and acts as a scavenger to Reactive 
Oxygen Species (ROS), unlike pheomelanin that is probably harmful 
after UVR exposure, via the generation of ROS and free radicals.  The 
amino acid tyrosine is catalyzed by tyrosinase to DOPA/DOPA quinone 
and further to eumelanin or pheomelanin, depends upon the, level of 
cyclic AMP (cAMP) ,the presence of cysteine and  activity of 
tyrosinase. Tyrosinase catalyzes the conversion of L-tyrosine to DOPA 
and further to DOPAquinone, which is required for the synthesis of 
both eumelanin and pheomelanin. The formation of pheomelanin 
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requires the presence of cysteine as well as less tyrosinase activity and 
less cyclic AMP (cAMP) than does the formation of eumelanin. 
DHICA-eumelanin is brown, DHI-eumelanin is black.The key factor in 
the production of melanin is the amino acid tyrosine, rate-limiting 
enzyme for melanogenesis are tyrosinase.  The activity of tyrosinase is 
increased by DOPA and is stabilized by tyrosinase related protein 1. If 
the tyrosinase gene (TYR) is mutated, no melanin can be produced 
leads to type 1b oculo cutaneous albinism . Several factors, including
e.g. α-MSH (α-melanocyte stimulating hormone, see below), Agouti 
signalling protein (ASP/ASIP), endothelin-1 (ET-1), basic fibroblast 
growth factor (bFGF) and UVR, influence the activity of the most 
important proteins involved in the melanogenesis (Park et al. 2009). 
The type and ratio of melanin produced (eu/pheo) depends on 
several different 16 melanogenic enzymes, the melanosome proteins 
(e.g. P protein and TRP1) and the availability of cysteine.  
Basal Skin Pigmentation (skin colours)     
The human skin colours/photo types are mainly dependent on the 
content and type of melanin distributed to the KCs, and on factors 
produced by KCs to regulate pigmentation .  
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EPIDEMIOLOGY
In Australia, which has the highest CMM incidence rates 
worldwide, the age-adjusted incidence rates were 34.6 (women) and 
46.1 (men) per      100 000 individuals in year 2005 (AIHW/AACR 
2008).    In Sweden cutaneous melanoma was the sixth and eighth most 
common cancer in women and men respectively in 2007, and the latest 
reported incidence of invasive melanoma was 2333 cases (1182 women, 
1151 men).  The intra epidermal melanomas (in situ) added another 
1146 cases (606 women, 540 men) (Social styrelsen 2008). The last 
reported average annual increase of all cancers in Sweden was 1.1% for 
women and 1.7% for men, but for melanoma this increase was 3.8% for 
women and 3.6% for men and thereby the most rapidly increasing 
malignant tumour in Sweden  . This rapid increase is evident also in 
other fair-skinned populations all over the world . The corresponding 
numbers in Sweden 2007 approached 24 (women) and 26.5 (men) per 
100 000individuals, reflecting that Sweden has some of the highest rates 
after Australia and New Zealand .  
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RISK FACTORS
Multiple risk factors play a major role for development of 
malignant melanoma. 
1. Skin type
2. Age
3. Gender
4. Tanning bed use
5. Previous melanoma
6. Sunlight exposure
7. Benign nevi
8. Family history
9. Genetic predisposition
10.Atypical mole and melanoma syndrome
15
SKIN TYPE
Skin, eye and hair phenotypes 
Red/blond hair, freckles, and blue/grey eye coloured people had 
more risk.  Present fair skin, poor tanning ability, often additionally 
light/red hair, light eye colours. 
These phenotypic characteristics are well known to have an 
association with the genes that regulate skin colour and pigmentation. 
One of these key genes is MC1R (see above). while others are only 
associated with red hair or red hair/fair skin but not with melanoma 
(Raimondi et al. 2008) risk factors that have been studied are e.g. 
indicators of actinic skin damage and a history of a previous 
premalignant or invasive nonmelanoma skin cancer (NMSC) (i.e. 
Actinic keratoses [AK], Squamous Cell Carcinoma [SCC]). These risk 
factors are also indicators of cumulative sun exposure. In addition, the 
freckling phenotype is also closely connected to the amount of UVR 
that the individuals have been exposed to (Gandini et al. 2005). This 
stresses the delicate balance between hereditary and environmentally 
causes of melanoma.
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Immunosuppression individuals with an immune deficiency  
(e.g. organ transplant recipients with immunosuppressive therapy and 
individuals with HIV/AIDS) have an increased risk to develop cancer, 
and the risk of melanoma has been shown to be 1.24 in HIV/AIDS 
patients and 2.34 in transplant patients. The comparable risk of NMSC 
was 4.11 for HIV/AIDS patients and 28.62 for transplant  patients .  
Inherited susceptibility to melanoma/Genetics About 90 % of all 
melanomas are sporadic and only 10% of all cases of melanoma occur 
in patients who have a hereditary predisposition for melanoma In the 
high-risk melanoma-prone families several cases of melanoma are 
present in multiple generations. The affected family members often 
develop multiple primary melanomas and are diagnosed at a younger 
age than non-familial sporadic cases. The observed increased melanoma
risk in relatives of melanoma cases is probably caused by both genetic 
factors and shared environmental exposure 1995). 
Skin phototypes
The skin phototypes are classified according to UVR reaction. 
Dark skin contains the same number and density of MCs as fair skin, 
and the basal pigmentation (“constitutive pigmentation”) thus depends 
on the level of the melanogenic activity of the MCs and on the transfer 
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of elanosomes to the surrounding KCs. This activity is mirrored in the 
number of produced melanosomes and in the efficiency of transporting 
the melanosomes to the KCs. The size of the melanosomes (smaller in 
fair skin), the type of melanin produced (eumelanin/pheomelanin ratio) 
and the rate of melanosome-degradation (occurring in mid-epidermis) 
of the KCs (smaller degrades faster) are also important element in the 
basal pigmentation. Eumelanin is present in large amounts in 
individuals with dark skin and hair. Whereas pheomelanin predominates 
in people with lower skin types 1 and 2.
UVR exposure results in alpha Melanocyte stimulating hormone , 
cortico tropic hormone and Endothelin release from the keratinocytes 
(KCs). α-MSH andACTH bind to the Melanocortin-1-receptor (MC1R), 
increase cyclic AMP (cAMP) and activate Protein kinase A (PKA), 
finally leading to increased levels of tyrosinase and hence increased 
eumelanin synthesis. UVR also damages the DNA of the cells, thereby 
activating the tumour protein p53 (TP53)-pathway to enhance DNA 
repair, apoptosis and allow for cell arrest. ETR=Endothelin receptor, 
MEK/ERK Mitogen-activated protein kinase2/Extracellular signal-
regulated kinase.
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Melanoma incidence ten times more common in caucasians than  
African Americans.  seven times more common in caucasians than the 
melanoma incidence of American Hispanics. In addition, while patients 
with light skin, red or blond hair, or blue eyes are more prone for 
increased risk of melanoma. 
AGE
The incidence of melanoma is 1.6 fold lower for men than 
women before 40years of age. At more than 65 years men is more 
incidence of melanoma than women.
GENDER
In general, men is higher incidence than female. 1.5 times higher 
risk for development of melanoma in male than a female risk.
TANNING BED USE
At more than 30 years or older, tanning bed use more than ten 
times of risk. Younger patients who use annually more than ten times of 
tanning and more than six times the risk of  developing melanoma 
compared with who do not use tanning beds. Number of years, hours 
and sessions directly proportional to increased risk of developing 
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melanoma. Since 2010, the  WHO lists use of tanning beds as a 
carcinogen.
Facultative Skin Pigmentation (Tanning) 
Tanning is when pigmentation increases above baseline as an 
effect of UVR exposure .Tanning ability is highly influenced by the 
genes responsible for skin pigmentation and thus the response to UVR, 
where mutated genes e.g. lead to defect melanin production or defect 
response to receptor stimulation. UVR affects MCs both direct and 
indirect (via effect on KCs). These events finally elevate the 
responsiveness of the MCs to α-MSH, increase eumelanin synthesis and 
enhance melanosome transfer and UVR exposure to existing 
pheomelanin leads to the production of ROS/free radicals , which 
probably contributes to the increased incidence of CMM and NMSC 
observed in red hair colour (RHC) phenotypes .  More specifically, 
Ultraviolet A radiation (UVA, 320-400 nm) is thought to mediate one 
of its tanning effects through oxidation of pre-existing melanin, which 
results in immediate pigment darkening (which fades after 8 hours). 
Delayed tanning is visible 48 to 72 hours after UVA and Ultraviolet 
B radiation (UVB,290-320 nm)) exposure, which is dependent on new 
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melanin formation via increased transcription of essential factors and
eventually increased tyrosinase activity.  
Alpha Melanocyte stimulating hormone   
Alpha-MSH is one of the melanocortin peptides (α-MSH, 
ACTH, and beta-endorphin),which plays an important role in the 
melanogenesis by inducing MC differentiation and melanin production.
All melanocortin peptides are produced by the proteolytic 
cleavage of the precursor protein POMC (Pro Opio MelanoCortin) and 
exert their effects through melanocortin receptors (MCR, see below). α-
MSHis produced in the pituitary gland, but also in the human skin by 
KCs, MCs and Langerhans cells. Increased production of  α-MSH by 
KCs is seen after UVR exposure .α-MSH together with ET-1 have been 
shown to: activate the KT-pathway (a prosurvival signalling pathway), 
enhance DNA repair (nucleotide excision repair [NER]), inhibit 
production of ROS and DNA photo products after UVR exposure and 
finally to promote eumelanin synthesis. Insummary, all these functions 
lead to increased survival of MCs after UV irradiation.
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Melanocortin-1 receptor/MC1R 
There are five major human melanocortin receptors and the most 
common seen on the surface of melanocytes is the melanocortin-1 
receptor (MC1R). The wild type allele of the MC1R that is predominant 
in the African continent is associated with dark skin and hair, as a result 
of promoted eumelanin production. When α-MSH (or ACTH) binds to a 
functional MC1R, the levels of cAMP increase and the levels of 
tyrosinase and several melanogenic enzymes are increased by 
transcription. With plenty of tyrosinase around, the synthesis of 
eumelanin is favoured instead of pheomelanin.The phenotypic 
advantages, with MC1R-variants, lighter skin and bright/red hair 
colours in northern countries with scarce UV radiation, are thought to 
be related to the vitamin D synthesis and the bone meta bolism .
PREVIOUS MELANOMA
Risk of developing second melanoma is 3 to 7% in patient have 
previous melanoma. This risk is compared in general population is more 
than 800 times in patients with previous melanoma.
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SUNLIGHT EXPOSURE
Increased risk of malignant melanoma associated with sun 
exposure, but a clear relationship has not been associated with malignat 
melanoma unlike basal cell carcinoma and squamouos cell carcinoma
who exposed to cumulative sun exposure. Number of severe and painful 
sunburn exposure is directly related with the increased risk of malignant 
melanoma. Patients who have a history of greater than eight severe 
sunburn  are more risk of developing melanoma. Sunlight effect is 
directly related to uv-B radiation but uv-A radiation role, has not been 
completely excluded.
History of sunburns (due to skin type)  
Intermittent sun exposure and history of severe sunburn were 
most strongly associated with melanoma while occupational 
(cumulative) exposure seemed to be protective in some studies (Gandini 
et al. 2005). One biologic explanation to the effect of intermittent 
exposure is that it causes DNA  damage in MCs but not enough to 
cause apoptosis. An accumulation of genetic mutations caused by 
incomplete DNA repair from every intermittent exposure could lead to 
malignant transformation over time. The risk associated with use of 
sunbeds is debated, as most epidemiological studies have found an 
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increased risk, especially in young users, but some have not . One 
hypothesis is that host response to UVR is more important than the dose 
and type of UVR exposure. In addition, it is problematic to estimate the 
individual’s exposure to UVR in retrospective studies, as study 
participants estimate the used amounts of sunscreen, the amount of 
UVR exposure and when the UVR exposure occurred subjectively and 
sometimes after a long latency. Moreover, multiple sunburns during 
childhood and adolescence and the increased risk of melanoma 
associated with that, might be influenced of recall bias and modified by 
the phenotype.
BENIGN NEVI
Who presented with more  than 50 nevi, all of which are more 
than 2 mm in diameter have 15 times the melanoma risk of persons with 
less than 5 nevi. Benign nevi not a precursor of melanoma.
FAMILY HISTORY
A family history of melanoma increases five times risk of 
developing melanoma .
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The ratio of sporadic and familiar melanoma.
The high-risk melanoma-prone families are under intense 
research and several underlying genes have been revealed. The 
melanoma genetics consortium, GenoMEL (www.genomel.org) is an 
organisation with melanoma research groups from 14 countries around 
the world pooling data, in order to elucidate the genetic field of 
melanoma and with a special interest for familiar melanoma.
GENETIC PREDISPOSITION
The heritable genes for melanoma susceptibility can vary from 
rare high-risk, high-penetrance genes to low-risk, low-penetrance genes
It is thought that the high-risk, high penetrance genes are 
responsible for the rare familial melanomas but not for the sporadic 
cases, which are instead probably caused by more common allelic 
variants (“polymorphisms”) in the moderate risk or low-risk. Some of 
the genes will be highlighted below.
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A family tree from a family with a heritdatary mutation in the 
CDKN2A gene, which is a high risk gene for melanoma.
Black circles-female melanoma , Male circles-male melanoma
CDKN2A-p16 MC1R CCND1 (cyclin D1) - High-risk genes
CDKN2A- p14ARF  PTEN- High-risk genes
CDK4  MITF- Moderate risk gene
Rb / RB  BRAF- Moderate risk gene
NRAS - Low-risk genes 
TP53 - Low-risk genes 
26
CDKN2A-the major high-risk gene. The major gene involved in 
melanoma development is the tumour suppressor gene CDKN2A, 
mentioned above (see cell signalling networks, Figures 7, 8.). Studies 
have shown that this high-risk gene is mutated in 20-40% of melanoma
prone families (with  ≥3 members affected by melanoma),  as compared 
to a mutation frequency of about 1-2 % in population-based melanoma 
patients. Mutations in the gene have also been linked to an increased 
risk of other tumours as e.g. pancreatic cancer (PC) and breast cancer .  
The encoded two gene products (p16, which is a negative regulator of 
cell cycle progression, and p14ARF which stabilizes p53) are both
tumour suppressors.  
The second gene product p14ARF binds to and prevents human 
double minute-2 (HDM2) from accelerating the degradation of p53, 
thus possessing tumour suppressive effects. p53 normally senses genetic 
damage and allows pause for DNA repair or activates apoptosis if there 
is too much DNA  damage. Decreased p53 leads to genetic instability 
when mutations and other genetic damage are left. A mutated p14ARF 
does not inhibit HMD2, which in turn accelerates the destruction of p53 
and thus enhances growth and survival of altered/damaged cells instead 
of cell cycle arrest and apoptosis.  Families with mutations in the exon 
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1β resulting in a mutated p14ARF protein have e.g. shown an 
association between melanoma and neural system tumours
CDK4 and RB/Rb--other high-risk genes 
As mentioned, the normal p16 protein binds to (and inhibits) the 
action of CDK4.Mutations in the CDK4 gene make the CDK4 resistant 
to p16 inhibition and thus give the same phenotypic results as for a non-
functional p16. Not inhibited CDK4 interacts with CCND1 and 
phosphorylates the RB/Rb protein, hence making RB/Rb inactive and 
allowing cells to unregulated pass the G1/S check point . Moreover, 
CDK4 amplification has been observed in sporadic melanomas, 
especially in acral and mucosal melanomas (Curtin et al. 2005).  
Families with germline mutations in the retinoblastoma gene (RB1), 
especially inherit a risk for retinoblastomas, but individuals who survive 
the retinoblastoma tumour also have a high risk for developing 
melanomas, as RB/Rb no longer can bind E2F and prevent unregulated
cell division. ARB1mutation is found in approximately 6 % of sporadic 
melanomas .
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ATYPICAL MOLE AND MELANOMA SYNDROME
Clinically Atypical nevi (CAN) 
Clinically atypical nevi/Atypical moles/Clark nevi/Dysplastic 
nevi are all names for the same nevus entity, but there is still no 
consensus on the nomenclature of this group. A problem is that the 
clinical features all too often do not correspond to the histopathological 
features, as a clinically atypical nevus can lack histological 22signs of 
dysplasia and vice versa. The histo pathological criteria are thus 
controversial without any general agreement .Clinically, CAN are 
pigmented macules, papules or plaques, most common on the scalp and 
trunk and with clinical features resembling melanoma such as 
asymmetry, red-brown-black colour, faded, indistinct or notched 
borders, fried egg appearance with a papule within a macula, concentric 
circles resembling a target(cockade nevus) and diameter > 5mm. An 
estimated two to eight percent of the population have CAN in the US, 
while one study from northern Sweden Showed a population-based 
prevalence of 11% . Another study  from the Swedish west coast 
reported population-based figures of as high as 18%. The onset of CAN 
is usually in older children and young adults and can be sporadic 
(non familial), as well as familial  or part of a syndrome. The presence 
of atypical nevi independently indicates a higher risk of melanoma, as 
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they can be both markers of and possibly even potential precursors for
melanoma .  
In case-control studies (which have shown an excess prevalence 
of CAN in melanoma cases relative to controls) and in cohort studies 
(which have shown an excess in  melanoma incidence both in familial 
melanoma kindreds with CAN and in patients with sporadic CAN 
relative to the general population) this correlation, with a higher 
melanoma risk, has been observed . More over, there seem to be a dose-
response relation between melanoma risk and the total number of CAN.
The causal genes that create the phenotype with excess CAN have not 
yet been fully elucidated, but several candidates exist. Data suggests 
possible linkage to loci on chromosomes 5, 7 and 9.
Atypical mole syndrome (AMS)
The observation that individuals with melanoma, from 
melanoma-prone families, often had an abnormal nevus phenotype with 
multiple common and atypical nevi/moles was first described in 1978 
by Clark as the “B-K-mole syndrome”. This phenotype has later been 
variously known as the dysplastic nevus syndrome (DNS) or the 
atypical mole syndrome (AMS). Different definitions of the same 
syndrome have been proposed, and thus literature is sometimes difficult 
to compare, but in 1983 Kraemer et al described a further subdivision of 
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the DNS, dependent on different melanoma risk categories, and on how 
many individuals per kindred that were affected by melanoma and 
atypical nevi, respectively . The initial study about the BK-mole 
syndrome referred e.g. to the last category “D-2”, but often different 
categories are intended when studies in general are referring to 
AMS/DNS, and the non-specific nomenclature can be confusing as 
AMS/DNS can be demonstrated both as a sporadic form and in different 
familial settings, and simultaneously with or without melanoma(s) . 
Description of the sporadic and the subgroups of the familial Atypical 
Mole Syndromes/ Dysplastic Nevus Syndromes, according to Kraemer 
et . The subgroup “D-2” is the group that is most commonly referred to 
as the “AMS/DNS”, when this is mentioned in familial studies. DN= 
dysplastic nevus, DNS= Dysplastic nevus syndrome, AN=Atypical 
Nevus, MM= malignant melanoma Just as the description of the 
syndrome is some what arbitrary, different authors have differently 
described the characteristics of the AMS phenotype .  However, most 
authors define the phenotype as one that presents “large numbers“ of 
common nevi over 2 mm in diameter and ≥2 CAN. Nevertheless, a 
more specific scoring system has been developed by Bishop et al. In 
conclusion, the presence of the AMS phenotype is associated with an 
increased risk of melanoma, both in the general population (as sporadic 
AMS/DNS) and in families.
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CLINICAL PRESENTATION
Clinical features of melanoma include color changes , irregular 
raised surface, increase size of lesion and surface ulceration. Physical 
examination particularly emphasis on the scalp, web space, 
intertriginous areas. A biopsy should be done on any pigmented lesion 
that undergos a change in size and color change. Nodal region, satellite 
and in transit lesion present in advanced melanoma
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PATHOGENESIS
Pathogenesis of the MC transformation into a melanoma cell is 
complex and the exact mechanisms are still not wholly understood. 
Both inherited and somatic 33 genetic events probably contribute, as 
well as environmental factors and increased production of ROS in 
the MC.  
At least three changes are required to transform a MC into an 
invasive melanoma; 
(i) something that initiates clonal expansion of the MC 
(e.g. mutations in proto oncogenes)
(ii) events that make the MC overcome cell senescence 
(e.g. influencing cell-cycle   control)
(iii) something that reduces or suppresses the apoptotic ability of the 
MCs (Bennett 2008).  
If mutagenic DNA in the MC escapes repair before cell division 
and if the cell cycle regulating mechanisms simultaneously cease to 
function, the melanocytes with DNA damage begin to divide in an 
uncontrolled manner, thus leading to the formation of a melanocytic 
33
tumour, a melanoma. Hence, dys regulations of the MC cell cycle 
control, of cell signalling mechanisms and aberrations in transcriptional 
control are all mechanisms underlying the oncogenesis of melanoma, 
together with other factors as availability of nutrients, activation of cell 
surface receptors and level of cellular stress. Recent research has also 
added theories about melanoma stem cells, which might probably 
change the view upon melanoma pathogenesis in the future. The 
mechanisms involved (so far known) will be briefly reviewed below. 
Three cell signalling networks; CDKN2A/RAS/Apoptosis  
Three major, interacting, signalling networks have been shown to 
be important:
(i) The tumor constraining CDKN2A network,
(ii) The growth-promoting RAS signalling network and
(iii) The key downstream regulator of apoptosis, the BCL-2 and 
p53     network .   The tumour-limiting CDKN2A network; 
One of the major genes involved in melanoma pathogenesis is 
found on chromosome 9 (9p21), and the gene is called CDKN2A 
(formerly MTS1/p16/p16[INK4A]). The gene (OMIM#600160)
encodes two gene products through alternative splicing: p16/INK4A 
34
and p14ARF (alternative reading frame). Both are acting as tumour 
suppressors. The tumour-constraining CDKN2A network regulates two 
critical cell cycle regulatory pathways, the Retinoblastoma (Rb/RB) 
pathway and the TP53/p53 pathway. Wild type CDKN2A  prevents 
cancer formation by mediating asenescence-like state upon oncogenic 
stress. CDKN2A acting as a brake on the cell cycle (p16) and by 
stabilizing p53 respectively. If CDKN2A 34 function is lost the 
opposite will occur with uninhibited cellular division, growth and 
proliferation .
The growth-promoting Ras signalling network with two cascades;
(RAS/MAPK and RAS/PI3K/AKT).
The NRAS proto-oncogene encodes the N-Ras/NRAS protein 
and is frequently (20%) found in its mutated oncogenic form in 
melanoma. Mutated forms of the RAS protein are constantly active, and 
in this state they activate e.g. the plasma membrane bound protein 
B-Raf / BRAF (akinase) and the PI3K (phossphatidylinositol-3-kinase). 
The RAS signalling network regulates cell growth, survival and 
invasion through two cascades. 
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(i) the RAS/BRAF/MAPK (mitogen-activated protein kinase) 
pathway, a major stimulus of melanocytic proliferation. 
(ii) (ii) the RAS/PI3K/AKT signalling stream, a promoter of 
melanoma progression and antiapoptosis/survival.
The RAS network with two cascades and the important steps with 
p16, p14ARF, Rb and TP53, regulating proliferation, DNA repair and 
apoptosis as well as growth and pro survival signalling. RTK= receptor 
tyrosine kinase, RB= Rb= Retinoblastoma protein, which in a native 
(hypo phosphorylated state) binds and inhibits the E2F transcription 
factor. This type of inhibition preventing G1-to-Stransition of the cell 
cycle, phosphorylation of RB, thereby inhibiting RB. E2F=a 
transcription factor. P16 inhibits the Cyclin D1/CDK4-mediated 
phosphorylation of RB. P14ARF inhibits human homolog of double 
minute 2 (HDM2), which otherwise inhibits the action of/accelerates the 
degradation of p53/TP5.  Isolated activation of the MAPK pathway 
leads to secretion of Insulin-like growth factor binding protein 7 
(IGFBP7), which in turn induces senescence through suppression of 
MAPK, as seen in common nevi. Melanomas however, block the 
IGFBP7 expression (in a so far unknown way) and escape this negative 
feed back loop, which leads to uncontrolled proliferation .
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The PI3K/AKT pathway is important in regulation of apoptosis, 
cell cycle progression, cell growth (cell mass increase), cell 
proliferation and survival gene transcription. Many Alterations in the 
PI3K pathway have been reported in 50-60% of melanomas. A further 
key component of the PI3K pathway is phosphatase and tensin 
homolog, another tumour suppressor gene, which is commonly altered 
(12-50%) in melanoma . Wild type PTEN acts as a tumour suppressor 
by removing phosphate groups and ctivates / dephosphorylates PI3K, 
and thereby suppresses cell survival and cell proliferation.  Loss of 
PTEN is often found in combination with BRAF mutations in 
melanomas on sites without chronic sun-exposure. PTEN has further 
been shown to be mutated in gliomas and endometrial cancers. germline 
mutations of PTEN have been found in cancer susceptibility syndromes 
(e.g. Cowden syndrome) .
The effector of the PI3K pathway is Akt/AKT=protein kinase 
B/PKB, and the subsequent proliferation, survival and invasion are 
promoted through AKT. AKT is inhibiting apoptotic processes, thereby 
promoting cell survival (see below). 
• The regulator of melanoma cell apoptosis; the BCL-2 and p53 
network. Two apoptotic pathways exist and converge: the intrinsic and 
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the extrinsic. Both pathways mediate cell death and they are important 
in understanding the survival as well as the chemotherapeutic resistance 
of melanomas. The intrinsic (mitochondrial) pathway is activated 
through several factors (including hypoxia, loss of growth factors and 
DNA damage) and is regulated bythe big B-cell lymphoma (BCL) -
family of proteins. BAK are finally responsible for mitochondrial 
permeabilization, which in turn leads to activation of caspases and 
apoptosis. The MAPK and PI3K/AKT pathways (see above) interact 
with the intrinsic pathway (Wang et al. 2007) and p53 up regulates the 
transcription of several pro-apoptotic genes e.g. BAX, PUMA and 
NOXA .
The extrinsic pathway involves activation of “death receptors” in 
the plasma membrane and downstream activation of caspases. This 
activation of caspases finally leads to apoptosis, as well as an activation 
of BID that interferes with the intrinsic pathway.  37 The balance 
between apoptosis and survival is delicate, both in normal MCs, nevi 
and melanomas, and high levels of anti apoptotic proteins have been 
found both in MCs, common nevi and in melanoma, which could partly 
explain the resistance to apoptosis .
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The tumour stem cell theory
A new model of cancer development has been suggested 
involving research about tumour /cancer stem cells (TSC/CSC). The 
model suggests that tumours, like melanoma, contain a subset of cells 
that is capable of both self-renewal and of giving rise to differentiated 
progeny If the growth potential of melanomas is based on a rare subset 
of melanoma stem cells, it is important to find out how to eradicate 
these cells. The TSC theory might explain how thin melanomas can 
metastasize and why metastatic melanomas are so difficult to treat. 
Nevertheless, the cell of origin to the TSC is still not known.     
PATHOLOGY
The major histo pathological types of malignant melanoma are as 
follows. Following histo pathological types has been traditionally 
described but prognosis is not dependent on the following descriptions 
but rather upon TNM staging.
1. Superficial spreading melanoma
2. Lentigo malignant melanoma
3. Acral lentiginous melanoma
4. Amelanotic melanoma
5. Nodular melanoma
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SUPERFICIAL SPREADING MELANOMA
Majority of patients included in this type upto 70%. Superfiial 
spreading mostly arise from pre existing nevus.
LENTIGO MALIGNA MELANOMA
This type constitute a small percentagae of malignant melanoma  
(4 to 10%) Lentigo maligna type are generally large size usually more 
than 3 cm at diagnosis before turn to invasive melanoma. More of 
patient in this type presented with long duration of in situ lesion. In 
general lentigo maligna type occur in more than 50years. Older white 
female are more commonly affected by this type.
AMELANOTIC MELANOMA
Darkish pigmentation changes not occurred in this types. More 
unlikely present and diagnosis is very difficult because of their lack of 
pigmentation. Factors such as change in size, asymmetry and borders 
irregular suggest possibility of amelanotic type of melanoma
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Dermoscopic appearance of superficial spreading melanoma                                  
Two nodular melanoma patients             
Oral cavity mucosal melanoma
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Acral  lentiginous melanoma arising from the sole of the foot    
Subunguval melanoma
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a) Histologic appearance of in situ melanoma with atypical 
melanocyte within epidermis
b) Superficial spreading melanoma Types-more proliferation of 
tumor cells in the epidermis
Lentigo melanoma types-very early lentiginous proliferation
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CLARK’S LEVEL FOR DEPTH OF INVASION  
1-Lesion confined to the epidermis,  
2 - Lesion extending to the papillary dermis 
3- Lesion filling the papillary dermis, 
4 -Lesion invading the reticular dermis 
5-  Cells invading the subcutaneous fat    
BRESLOW TUMOR THICKNESS
The pathologist measures in millimetres the distance between the 
granular layer in the epidermis and the deepest invasive melanoma cell
1) <1.0mm
2) 1.01 to 2.0mm
3) 2.01 to 4.0mm
4) >4mm
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DIAGNOSIS
Biopsy of primary lesion is mandatory for histo pathlogical 
confirmation. Choice of biopsy varies depends upon site of lesion as 
well as shape of lesion. Excisional biopsy or an incisional biopsy using 
a scalpel or blade is acceptable. Punch biopsy performed if patients 
presented with proliferative growth. Full thickness biopsy into the 
subcutaneous tissue mandatory for proper T staging. Small 
sizemelanoma should be excised with 1 to 3 cm margin.
Fine needle aspiration cytology used for diagnosing of nodal and 
extra nodal systemic metastases. FNAC not used for diagnose primary 
melanoma. Ultrasonagram and magnetic radiological imaging of 
primary melanoma helpful for extent, adjacent structure involvement. 
USG more commonly used for diagnose nodal region if clinically not 
identified. CT chest, abdomen and CT brain more useful for diagnose of 
any systemic spread.
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TREATMENT
MANAGEMENT OF LOCAL DISEASE
Surgery is primary modalities of treatment of early stage of 
malignant melanoma. Wide local excision is generally done in early 
stage of melanoma. Wide local excision means wide excision of tumor 
down to but not generally including the deep fascia with margin of 
normal skin.
TUMOR  THICKNESS EXCISION MARGIN
In situ lesion 0.5 to 1 cm
<1mm 1cm
1-2 mm 1-2 cm
2-4 mm 2cm
>4 mm 2cm
Usually thin melanoma size of < 1mm adequate margin 1 cm is 
needed for wide local excision. Intermediate melanoma size of 1-2 mm, 
wide local excision with 1-2 cm margin. Intermediate melanoma size of 
2-4 mm excised with 2 cm margin. Thick melanoma >4mm size excised 
with 2 cm margin.
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WOUND CLOSURE
Various options available for wound closure include primarily 
closure, local advancement flap, graft and distant flaps. Primarily 
closure is the treatment of choice for most of early melanoma. 
Longitudinal incision used for extremities melanoma. skin crease 
incision require for trunk and head and neck melanoma. Wide local 
excision included removal of growth, skin and subcutaneous tissue are 
removed down to deeply but deep fascia not included in excision 
specimen.
Lazy ‘s’ pattern of incision oriented to allow primary closure. 
Two layer of closure is usually performed in wide local excision. A 
dermal layer using 3-0 absorbable sutures. More importantly orientation 
of specimen is must for accurate assessment of histopathological 
margins.For extremities melanoma, generally skin graft must be 
harvested from opposite limb. Usually graft harvested away from the 
satellite lesion and in transit lesion. Satellites lesion usually occur 
within 2 cm of primary lesion. Intransit lesion usually present 2 cm 
beyond the primary lesion but within regional nodal basin. Local 
advancement flaps is mostly tried if primary closure is not possible.
Transposition flaps, distant flaps and rotation flaps of many varieties 
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used for wound closure if primary closure and local flap not possible for 
closure of lesion after wide local excision.
Mucosal melanoma including mucosa of respiratory tract, anal 
canal and vagina had generally poor prognosis. For these mucosal 
melanoma, generally not advice aggressive surgical treatment. 
Abdomino perineal resection not generally recommend for anal canal 
melanoma. Local excision of anal canal is mostly done for all patients. 
Adjuvant radiation therapy given for mucosal melanoma to reduce the 
risk of loco regional recurrence. 
MANAGEMENT OF REGIONAL LYMPH NODES
Two terminology commonly used in treatment of regional 
lymphnodes. Clinically and imaging studywise palpable lymphnode or 
nodal secondaries confirmed by fine needle aspiration cytology, these 
positive nodal secondaries patient treated with delayed or therapeutic 
lymph node dissection (TLND). Clinically node negative lymph node 
patients treated with prophylactic  or elective lymph node dissection 
(ELND).More recently selective approach to regional lymph node 
followed by most of surgeon especially in treatment of melanoma. 
Sentinel lymph (SLN) identification developed by mortan et al. Another 
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recent technique is intraoperative lymphatic mapping used for diagnosis 
of clinically negative, FNAC negative, N0 node patient.
THERAPEUTIC LYMPH NODE DISSECTION
Patients with known regional lymph node metstases undergo 
therapeutic lymph node dissection. Main drawback of TLND is 
delaying treatmet until appearance of lymph node metastases are both 
clinically and imaging studywise detectable positive lymph node 
secondaries. These delaying of treatment may result in development of 
distant micrometastases at the  time of lymphadenectomy. Reduced 
curative rate for above patients.
ELECTIVE LYMPH NODE DISSECTION
In early stage of melanoma, theoretical advantage of treating 
lymphnode metastases in the natural history of the disease. Main 
drawback of ELND is that many patients undergo lymph node surgery 
who do not have regional lymph node metastases. Better chance of 
prognosis (50 to 60%) in patients with clinicall negative, FNAC wise 
positive lymph nodes undergo elective lymphnode dissection compared 
to patient did not undergo elective lymphnode dissection. Thin type of 
melanoma size of less than 1 mm not benefited by sentinel lymphnode 
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dissection because lymph node involvement very rare in thin melanoma. 
Mostly intermediate type of melanoma size of 1 to 4mm patient mostly 
useful for intraoperative lymphatic mapping and sentinel lymphnode 
biopsy.
SENTINEL LYMPH NODE BIOPSY TECHNIQUE  
Lymphatic mapping and SLND is performed mostly in N0 
patients (clinically and radiologically negative lymphnode). Isosulfan 
blue dye used for staining the primary node. blue dye injected around 
the tumor site or biopsy site and the isosulfan blue dye is taken up by 
the lymphatic system and spread thorough afferent lymphatic to the 
primary node in regional drainage area. (sentinel node) sentinel node is 
first draining lymphnode are identified by uptake of isosulfan blue dye . 
85% cases of sentinel node approximately identified by use of isosulfan 
blue dye alone. Remaining 15% of cases not benefited by sentinel 
lymphnode biopsy. Overcome the false negative result of sentinel  
lymph node dissection. More recent advanced techniques have been 
used for significantly improved SLN localization a) pre operative lymph 
scintigraphy b) Intraoperative technetium 99 labeled sulphur colloid 
scan c) Intraoperative use of hand held gamma probe.
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Technique of intra operative lymphatic mapping and SLNB
Radioisotope labelled tracer is generally injected intra dermally 
3hours preoperatively
A-at the time of surgery
B-sentinel node identified preoperatively
C-pathologic examination by serial sectioning demonstrates a sub 
scapular nodal metastasis
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INCIDENCE OF POSITIVE SENTINEL LYMPH NODES
Stage 1a- 1%
stage 1b – 8%
stage 2a – 22%
stage 2b – 31%
stage 2c – 49%
The  incidence of positive sentinel lymph nodes for stage 1a, 1b, 
2a, 2b , and 2c were 1%, 8%, 22%, 31% and 49% respectively.
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PATHOLOGIAL EVALUATION OF SENTINEL LYMPH 
NODES
Usually fever lymph node submitted to pathologist by sentinel 
lymph node technique compared with complete lymph adenectomy. 
Several antibodies directed against melanoma associated antigens like s-
100, HMB-45, tyrosinase, MART-1 and MAGE3 are commonly used 
for immune histochemistry study. S-100 is low specificity and more 
sensitive antibodies. HMB-45, MAGE 3 and tyrosinase is more 
specificity and low sensitivity. Frozen section evaluation is 
controversial for sentinel lymph node evaluation in management of 
malignant melanoma. Formalin fixed, paraffin embedded samples block 
generally used for examination of sentinel lymphnode examination. 
other technique is touch preparation or cytologic analysis of specimens 
are used. Sometimes even combination of IHC and histological 
examination of sentinel lymph nodes may fail to diagnose isolated 
melanoma cells or oligocellular deposits. With use of reverse 
trascriptase – polymerase chain reaction (RT_PCR)identify even in 
background 1 * 1000000 to 1* 10000000 normal cells can be identified.
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Current practise guidelines for the case of sentinel lymphnode 
biopsy.
Thin melanoma (<1 mm) not indicated for sentinel lymph node 
biopsy because overall very very low incidence of positive lymphnode 
identified by SLNB technique. Identification of doing SLNB is patients 
who are stage 1b (<1 mm thick with ulceration or mitotic rate >1 
mitosis per mm square or 1 to 2 mm thick without ulceration).Stage 2a 
and stage 2b (1 to 2 mm thick with ulceration or >2mm thick ) patients 
have indication for performing sentinel lymph node dissection. NCCN 
does not recommend in low risk patients like breslow thickness <0.5 
mm and< mitosis per mm2 for performing sentinel  lymohh node 
biopsy.
AXILLARY DISSECTION
Complete axillary dissection means all three level node in axilla 
must be removed. Axillary node include anterior, posterior, central, 
lateral and apical lymp node. Horizontal, ‘s’ shaped incision used 
generally. Skin flaps are raised in all four direction. Important vital 
structure include nerve to lattismus dorsi, nerve of bell, axillary vessel 
and cephalic vein preserved. All node level 1, 2 and 3 removed. 
Hemostasis secured. 15 F closed suction catheter is kept in axilla cavity 
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through the inferior flap. Drainage tube removed postoperatively 
secretion if less than 30ml per day for two consecutive days or 
minimum3-4 wks duration after surgery.
GROIN DISSECTION
A reverse lazy s incision is mostly used for groin lymph node 
dissection. Incision start from superomedial to the anterior superior iliac 
spine. Incision extend vertically down to inguinal crease, obliquely 
across the inguinal crease. Skin flap raised medially upto pubic tubercle, 
laterally to the lateral border of sartorius muscle.  Skin flap raised 
vertically  3 to 5 cm above the inguinal ligament and vertically below 
upto apex of the femoral  triangle. All the node in inguinal region both 
vertical and horizontal group removed along with lymphatics. Cloquet’s 
node is important node for whether iliac dissection need or not. Femoral 
nerve and femoral vessel must always preserved. Only great saphenus 
vein removed if wanted. Sartorius musle transposition used to prevent 
the exposed femoral vessel. DT kept in all cases. Drainage tube
removed if less than 30 ml per day for two consecutive days. Mostly 3 
to 4 weeks, the drainagae tube are removed.
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INDICATION OF THE ILIAC AND OBTURATOR NODES
a)Involvement of iliac and obturator node diagnosed pre operatively
b) Superficial lymph node dissection specimen show more than three 
grossly positive lymph node.
c)Frozen section examination show positive of cloquet’s node 
metastasis.
ADJUVANT THERAPY FOR LOCOREGIONAL DISEASE
A. INTERFERON  ALPHA 2b
B. CHEMOTHERAPY
C. RADIOTHERAPY
D. MONOCLONAL ANTIBODIES
INTERFERON ALPHA 2b
High dose interferon alpha 2b is used for patients with melanoma 
who have a high risk of recurrence. Patients with locally advanced 
disease, recurrent disease, nodal recurrence, in transit or satellite disease 
are indication for high dose interferon alpha 2b. Doses of interferon 
alpha 2 b was 20 million unit/m square/day itravenously for 4 weeks 
followed by 10 million units per m square three times a week 
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subcutaneously for nexy 2 days. Recently PEG-IFN ALPHA-2b 
approved for treating gross nodal and microscopic secondaries 
melanoma patients. This drug treatment should be started within 3 
month of definitive surgical procedure. Doses recommendation is 
6microgram/kg/week subcutaneously for 8 doses followed by 3 
microgram/kg/week subcutaneously for upto 5 years.
CHEMOTHERAPY
Most of the study describe no benefit of use of adjuvant 
chemotherapy in melanoma patient who are at high risk for relapse. 
Only some benefit of survival who treated with adjuvant chemotherapy. 
MONOCLONAL ANTIBODIES
Iphilimumab is monoclonal antibodies now being studied in 
adjuvant treatment setting.  
MANAGEMENT OF IN TRANSIT DISEASE
Recurrent local regional disease found in the dermis or 
subcutaneous tissue beyond 2 cm away from primary lesion but within  
primary nodal drainage region. 3 to 9%  of cases presented with in 
transit lesion. Chance of occurrence of in transit lesion is high who 
presented with lower extremity primary tumor, age more than 48 yrs 
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,thick melanoma according to breslow thickness, ulceration and nodal 
involvement.
In patient with in transit lesion, more than 60% chance of 
regional lymph node involvement. More chance of disease recurrence in 
patient had positive sentinel lymph node, size of in transit tumor more 
than 2 cm, disease free interval less than 12 months before occurrence 
of in transit recurrence.
Melanoma patients with in transit metastases confined to limb not 
amenable for standard surgery, regional chemotherapy techniques is 
used. Two type of regional chemotherapy used such as isolated limb 
perfusion and more recently isolated limb infusion. Amputation is 
rarely indicated nowdays.
HYPERTHERMIC ISOLATED LIMB PERFUSION
Melphalan is used in isolated limb perfusion traditionally. 
Procedure, first cannulae are inserted and tourniquet is applied  at upper 
level of limb followed extremity is placed on extra corporeal by pass 
circuit. 8% to 82% response (complete response rate-41%, partial 
response rate- 31%) can be achieved with use of regional chemotherapy 
technique with melphalan alone. High complete response rate 88% are 
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achieved with combination chemotherapy. More commonly following 
combination chemotherapy are used include melphalan, tumor necrosis 
fator alpha, interferon gamma. These type of regional chemotherapy 
technique take long operating times, expensive equipment procedure is  
complex and invasive and considerable ancillary staff. In an attempt to 
achieve similar result, a new regional chemotherapy technique, isolated 
limb infusion has been recently developed.
ISOLATED LIMB INFUSION
Low flow perfusion performed via percutaneously inserted 
catheters. Oxygen circuit not used in isolated limb infusion. Here 
catheter inserted into unaffected limb and catheter advanced 
intravascularly to the tumor limb. General anaesthesia needed for 
performing this technique. Generally melphalan and actinomycin-D 
types of chemotherapy used. Main mechanism of these technique 
damage of tumor cells are more effectively occurred under hypoxia and 
acidosis. Overall response rate 82% (complete response rate 38%, 
partial response rate 40%)
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MANAGEMENT OF LOCAL RECURRENCE
Single lesion of local recurrence in patient with primary 
melanoma had  good prognosis treated with wide local excision similar 
to primary treatment. Multiple, small and superficial lesion may be 
treated in a similar way to that used for patients with in transit disease. 
MANAGEMENT OF DISTANT METASTASES
Common sites of recurrence in decreasing frequency order, 
distant skin and subcutaneous tissues (39%), lungs (11 to 34%), liver 
and brain. Poor prognosis in patient with systemic metastasis had lower 
survival ranging from 6 to12 months. Only palliative use of 
radiotherapy and chemotherapy if patients with systemic metastasis but 
little benefit of palliative treatment. surgery is also a very useful 
palliative treatment for isolated accessible distant metastases.
TARGETED THERAPY
a)BRAF inhibitors
The BRAF gene encodes for origin of B-RAF , a protein involved 
in tumor growth. BRAF mutation have been identified in 50% of 
invasive cutaneous melanoma. BRAC inhibitors, PLX4032 
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(vemurafenib) used in unresectable, stage 3 c or stage 4 melanoma 
patients with presence of mutated BRAF gene.
b) KIT Inhibitors
Single agent chemotherapy generally used for metastatic 
melanoma. Dacarbazine is the drug of choice used for distant metastatic 
melanoma. Dartmouth regimen (dacarbazine, cisplatin, carmustine and 
tamoxifen) also used, response rate 55% overall and complete response 
rate 20% in patient treated with Dartmouth regimen. 
RADIATION THERAPY
A case were inability to obtain wide margins, satellitosis, 
desmoplastic melanoma, adjuvant radiation to primary tumor region 
more useful. Adjuvant radiation to regional nodal region has been 
clearly defined. Indication of adjuvant radiotherapy include multiple 
positive nodes, one or more metastatic  node more than 3 cm and 
extranodal spread.
External beam radiation therapy provide long term local control 
and more effective palliation. Recurrent subcutaneous and nodal 
disease, symptomatic bone metastasis benefited by adjuvant radiation 
therapy.
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FOLLOW UP AND SURVEILLANCE
Early Stage  melanoma (insitu or 
<1 mm thick, non ulcerated, no 
lymphnode)
Every 6 months for 2 years and 
then annually
Thicker or ulcerated melanoma or 
positive lymphnode
Every 3to 4 months upto 3 years, 
every 6 months next 2 years and 
then annually
At each visit, patient undergoes a physical examination, skin 
survey and serum LDH level. Radiographic evaluation is generally not 
performed in stage 1 and stage 2 melanoma. Chest x ray is generally 
done at each follow up except in situ and thin melanoma. Stage 3 (or) 
stage 4 disease CT or PET/CT scan should be considered every 6 to12 
months. Patients with stage 3c or stage 4 melanoma, MRI of the brain 
can be considered. USG of regional lymph node not well established for 
surveillance of patients with stage 1 to 3 disease. 
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MATERIALS  AND  METHODS
SELECTION OF CASES
Cases admitted in all surgical units of department of general 
surgery, dermatology department, plastic surgery department and 
oncology department in Stanley government hospital between may 
2011 to December 2013 were taken in a random fashion for this study. 
This group of 30 patients were aged between 30 to72 years with a mean 
age of 50 yrs. Of these 18 were male and 12 female.
Patients with blackish discoloration of skin were admitted with a 
provisional diagnosis of malignant melanoma. 10 cases were admitted 
in this fashion. 2 cases present with oral blackish discoloration.
Seven patients presented with growth in skin, 2 patients presented 
with ulcer in skin, 4 patients presented with swelling in lymphnode  
region and 5 patients presented with anal growth.
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INVESTIGATIONS DONE
All the patients admitted in surgery department underwent 
baseline investigations including complete hemogram, urine 
analysis,blood sugar, renal function tests like blood urea and serum 
creatinine, and serum electrolytes. All patients had liver functions tests 
done and one patients with liver secondaries had elevated bilirubin -
4mg% with a normal SGOT,and SGPT serum albumin was low in in 
patient 2.8g%.
Three patients were known diabetic on oral hypoglycemic drugs 
and two patients was found to be a diabetic. Chest x ray and ECG was 
done in all patients. No patient in our series had brain . All patient 
underwent full thickness biopsy of growth and blackish discoloration 
lesion was sent for histopathological examination and confirmed as 
malignant melanoma of various region like cutaneous and mucosal 
melanomas. Serum LDH, USG abdomen was done in all patients. 
MRI of primary region done only for clinically locally advanced 
disease patient. USG of primary nodal basin region done for clinically 
non palpable locally advanced and metastatic disease patients .CT brain, 
CT chest and CT abdomen done only for suspicious metastasis patients. 
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One patients presented with lung secondaries. None of the patients 
underwent sentinel lymph node biopsy.
All patients after admission were hydrated well with IV fluids 
and compatible blood transfusion were given in 2 patients with 
anaemiaand their general condition and nutritional status were 
improved. Diabetics patients, glycemic status  controlled with insulin 
and cancer treatment was then planned.
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RESULTS
These 30 patients were divided into two main group. Group A 
were curative resection was planned and Group B were palliative 
treatment was planned.
GROUP A
Included 24 patients for curative resection
- no distant visceral metastasis
- no local fixity to surrounding important structures
- no fixed regional lymphnode
GROUP B 
Included 6 patients for palliative treatment
- Palliative resection (2 patients)
- Palliative chemotherapy (2 patients)
- Palliative radiotherapy (3 patients)
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SURGERY IN GROUP A PATIENTS
24 patients of this group underwent a wide local excision by skin 
crease incision in trunk, longitudinal incision in extremities 7 patients of 
this group underwent therapeutic radical lymphnode dissection with 
wide local excision. No local fixity to bone and neurovascular bundles, 
no fixed metastatic lymphnode, no distant visceral metastasis like liver, 
lung and brain in group A patients.
TREATMENT IN GROUP B PATIENTS
6 patients belonging to this group. Two patients presented with 
distant visiceral metastasis, one presented with extremities growth with 
liver secondaries. Another one patient presented extremities growth, 
inguinal lymphnode bilateral fixed node with involvement of lung 
secondaries. These above two patients underwent palliative 
radiotherapy and palliative chemotherapy. Three patients presented with 
unresectable extremities growth with fixed lymphnode metastasis. 
These three patient underwent palliative chemotherapy and palliative 
radiotherapy. One patient presented with in transit lesion and this 
patient underwent palliative chemotherapy and isolated limb perfusion.
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POST OPERATIVE PERIOD
All the patients underwent wide local excision with therapeutic 
radical lymphnode dissection hada continuous drainage tube for a 
period ranging from 2 weeks to 3 weeks. 5 patients underwent 
abdominoperineal resection. These 5 patients had a continuous 
intraabdominal drains were removed on day 10 to 14th day and most of 
the patients were discharged on day 8 on the average and were reviewed 
regularly for follow up.
5 patients developed wound infection and gaping and had to 
undergo secondary closure. 3 patients developed flap necrosis and had 
to undergo flap revesion and skin graft. Two paients keep the draiage 
tube in nadal region for 4 weeks and managed conservatively.
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FOLLOW UP
All the patients advised regular follow up every 3 to 4 months for 
first 2 years palliative chemotherapy was given in 5 patients with 
decarbazine, cisplatin and vinblastine chemotherapy. Palliative 
radiotherapy was given in 2 patients they had good symptomatic relief 
for few months, but few patients lost follow up after 6 months.
Among group B patients, 4 patients develop distant metastasis. 
Among group A patients, 5 patients develop local recurrence, these 5 
patients underwent wide local excision with radiotherapy. 1 patient 
develop recurrence distant skin and subcutaneous tissue and this 
patients underwent debulking excision, palliative radiotherapy and 
chemotherapy.
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DISCUSSION
In our series of 30 patients, proved to have malignant melanoma, 
male comprised 60%  and females only 46%.
SEX NO %
Male 18 60%
Female 12 40%
Of these patients, most of them fall into the age group 40 to 
60years, the range being 30 to 72 years and the mean age being 52 
years.
Class interval age in years No. %
30-39 4 13.3
40-49 10 33.3
50-59 11 36.6
60-72 5 16.6
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SEX INCIDENCE IN 30 CASES OF MALIGNANT 
MELANOMA
Male 18 patients (60%)
Female 12 patients (40%)
MALE
FEMALE
AGE INCIDENCE IN 30 CASES OF MALIGNANT MELANOMA
30-39years-13.3%
40-49years-33.3%
50-59years-36.6%
60-72years-16.6%
0.00%
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At presentation, 63.3% patients presented with skin growth. 10% 
patients presented with ulcer lesion. 12% patients presented with 
blackish discoloration of skin and mucosal site include oral cavity and 
anal canal region.
SYMPTOM NO. %
Skin growth 19 63.3%
Blackish discoloration 10 33.3%
Ulcer 12 40%
lymphnode swelling 7 23.3%
Anal canal growth 5 16.6%
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On clinical examination, 19 patients had an growth lesion with or 
without ulcer lesion. 4 patients had satellite nodule present within 2cm 
of primary lesion. 1 patient presented with in transit lesion. 4 patients 
presented with clinically lymphnode metastasis. 2 patients had 
lymphnode detected by ultrasonogram and CT scan.
SIGN NO. %
Growth with or without    ulcer 19 63.3%
Satellite nodule 4 13.3
In transit lesion 1 3.3
Lymphnode metastasis 4 13.3
Anemia 2 6.6
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At presentation, most of the patients had extremities growth ad 
ulcer lesion.  15 patients included in extremities melanoma lesion. 6 
patients present with growth and ulcer present in trunk. 5 patients had 
growth present in anal canal. 2 patients had oral cavity and blackish 
discoloration lesion present.
LOCATION NO. %
Trunk 6 20%
Upper extremities 7 23%
Lower extremities 8 26.6%
Oral cavity 2 6.6%
face 2 6.6%
Anal canal 5 16.6%
LOCATION OF MELANOMA INIDENCE IN 30 CASES OF 
MALIGNANT MELANOMA
1) Upper extremities
2) Lower extremities
3) Trunk-20%
4) Anal canal-16.6%
5) Face and oral cavity each separately
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-26.6%
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Among the 30 patients in our series only 7 patients underwent 
therapeutic radical lymphnode dissection. Most of the patients could 
achieve a curative resection. 24 patiets underwent wide local excision. 5 
patients underwent abdominoperineal resection. 5 patients completed 
palliative chemotherapy and radiotherapy.
TREATMENT OPTION NO. %
Wide local excision 19 63.3%
Therapeutic radical 
Lymphnode dissection
7 23.3%
Abdominoperineal resection 5 16.6%
Toe amputation 2 6.6%
Palliative radiotherapy 2 6.6%
Palliative chemotherapy 3 10%
TREATMENT MODALITIES
1)  WLE-63.3%
2)  TRLNE-23.3%
3)  APR-16.6%
4)  PRT-6.6%
5)  PCT-10%
6)  TA-6.6%
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20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
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Based on histopathologial examination after resection, the tumour 
thickness classified based on breslow’s description. Thin melanoma < 
1mm no patient in my study. Intermediate melanoma thickness range of 
1 to 4mm, 36.66% of patients present. Thick melanoma thickness range 
of >4mm, these class of patients mostly present in my study 73.3% 
patients included in thick melanoma group.
BRESLOW TUMOUR 
THICKNESS
NO. %
<1.0 MM _ _
1.01 – 2.0MM 3.3 10%
2.01 _ 4.0MM 8 26.6%
>4MM 22 73.3%
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BRESLOW CLASSIFICATION
BLUE-Thick  melanoma-73.3%
RED-Intermediate melanoma-26.6%
GREEN-Thin melanoma-10%
1st Qtr
2nd Qtr
3rd Qtr
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Based on clinico pathological TNM staging most of the patients 
in my study included in stage 3. 46.6% patients included in stage 3. 
36.6% patients included in stage 3. 36.6% patients included in stage 2. 
Only few patients presented with stage 1 and 4 diseases.
clinico pathological 
stages
no. %
stage1 3 10%
stage 2 11 36.6%
stage 3 14 46.6%
stage4 2 6.6%
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CLINICO PATHOLOGICAL STAGE -  TNM STAGING
 Stage 1---10%
 Stage 2---36.6%
 Stage 3---46.6%
 Stage 4---6.6%
STAGE 1
STAGE 2
STAGE 3
STAGE 4
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In the past operative period, the commonest complication was 
wound infection and flap necrosis. 8 patients presented with wound 
infetction. 10% had flap necrosis occurred.Each of the following 
complicationlike lymphedema, lymphorrhea and paresthesia presented 
in 6.6% of patients.
COMPLICATION NO %
Wound infection 8 26.6%
flap necrosis 3 10%
Lymphorrhea 2 6.6%
Lymphedema 2 6.6%
Paresthesia 2 6.6%
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CONCLUSION
 Mean age at presentation was 50 years
 46.6% of patients had stage 3 disease at presentation
 Most of the cases in this series are extremities melanoma
 Curative wide local excision was possible in 63.3% of 
cases
 Blackish patches, ulcer and growth were the commonest 
complaints
 Prognosis of the patients in my study better in patients 
without ulceration and lymph node involvement.
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PROFORMA
• NAME : SL. NO:
• AGE /SEX:
• ADDRESS WITH CONTACT NUMBER:
• IP NO:
• DATE OF ADMISSION:
• DATE OF SURGERY:
HISTORY OF PRESENTING ILLNESS:
 Mole -number, site, color changes, diameter changes, 
progression
 Growth–size, site, duration
 Ulceration-site, duration
 Swelling in lymph nodal region
 pigmentation of skin
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PAST HISTORY:
 WHETHER A KNOWN CASE OF DM/HYPERTENSION/  
ASTHMA/TB/EPILEPSY/CARDIAC ILLNESS
 H/O SIMILAR EPISODES IN THE PAST, IF ANY:
 H/O  sunlight exposure
FAMILY HISTORY:
TREATMENT HISTORY:
CLINICAL EXAMINATION:
GENERAL EXAMINATION:      temp:            p.r:         bp:
SYSTEMIC EXAMINATION:
CVS
RS
PER ABDOMEN                CNS
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LOCAL EXAMINATION:
Growth in  skin :       present/ absent                 
Ulceration:    present/ absent   
Lymphadenopathy :  present/  absent           
Changes in mole:          present/ absent                                                                                                              
CLINICAL DIAGNOSIS:
INVESTIGATIONS:
1.ROUTINE INVESTIGATIONS: CBC, RFT,LFT,CXR,ECG
2.BIOPSY-INCISIONAL/EXCISIONAL
3. USG, CT SCAN, MRI SCAN     
4.  FNAC OF LYMPH NODE  ,SENTINAL NODE BIOPSY     
5.  SERUM LDH 
SURGERY DONE:
HISTO PATHOLOGICAL REPORTS:
FOLLOW UP:
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ABBREVIATION
A.G –Anal canal growth, S.G –Skin growth, U-ulcer, LN-lymph 
node swelling , B –blackish patch, S –Satellite nodule,  I –Intransit 
lesion ,  TA –Toe amputation , APR –Abdominal perineal resection, 
H–Hystrectomy, WLE –Wide local excision, TRNLD –Threapeutic 
radical lymph node dissection,  RT –Radiotherapy, CT –Chemotherapy,  
AF –advancement flap, ILP –Isolated limp perfusion,  SS –Skin and 
subcutaneous tissue, L–Local recurrence, LNR –Lymph node 
recurrence.
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REVISED TNM CLASSIFICATION
This classification system was updated in 2009 by the AJCC.
T 
Classification
Thickness Ulceration Status
Tis N/A N/A
T1 ≤ 1.0mm
a: w/o ulceration and mitosis < 1 / 
mm2
b: with ulceration and mitosis ≥ 1 / 
mm2
T2 1.01-2.0mm
a: w/o ulceration
b: with ulceration
T3 2.01-4.0mm
a: w/o ulceration
b: with ulceration
T4 > 4.0mm
a: w/o ulceration
b: with ulceration
N 
Classification
# of Metastatic Nodes Nodal Metastatic Mass
N0 No evidence of lymph node metastasis
N1 1 node
a: micrometastasis
b: macrometastasis
N2 2-3 nodes
a: micrometastasis
b: macrometastasis
c: In transit metastases/satellites 
without metastatic nodes
N3
4 or more metastatic nodes, or matted nodes, or in-
transitmetastases/satellites and metastatic nodes
M 
Classification
Site Serum LDH
M0 No evidence of metastasis to distant tissues or organs
M1a
Distant skin, subcutaneous or 
nodal metastases
Normal
M1b Lung metastases Normal
M1c
All other visceral metastases
Or any distant metastases
Normal
Elevated
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